Patents by Inventor Patricia Pietrobon

Patricia Pietrobon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11419930
    Abstract: This disclosure relates to methods for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject. The subject may be at risk for a primary symptomatic C. difficile infection. In some embodiments, a method is for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject at risk for a primary symptomatic C. difficile infection, and comprises administering to the subject a composition comprising C. difficile toxoid A and toxoid B at least three times, each administration being about seven days apart.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: August 23, 2022
    Assignee: Sanofi Pasteur, Inc.
    Inventors: Patricia Pietrobon, Ginamarie Foglia, Guy De Bruyn, Sanjay Gurunathan
  • Publication number: 20210145956
    Abstract: This disclosure relates to methods for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject. The subject may be at risk for a primary symptomatic C. difficile infection. In some embodiments, a method is for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject at risk for a primary symptomatic C. difficile infection, and comprises administering to the subject a composition comprising C. difficile toxoid A and toxoid B at least three times, each administration being about seven days apart.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 20, 2021
    Applicant: Sanofi Pasteur, Inc.
    Inventors: Patricia Pietrobon, Ginamarie Foglia, Guy De Bruyn, Sanjay Gurunathan
  • Publication number: 20200113991
    Abstract: This disclosure relates to methods for eliciting an immune response against C. difficile toxin A and toxin Bin an adult human subject. The subject may be at risk for a primary symptomatic C. difficile infection. In some embodiments, a method is for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject at risk for a primary symptomatic C. difficile infection, and comprises administering to the subject a composition comprising C. difficile toxoid A and toxoid B at least three times, each administration being about seven days apart.
    Type: Application
    Filed: October 21, 2019
    Publication date: April 16, 2020
    Applicant: Sanofi Pasteur, Inc.
    Inventors: Patricia Pietrobon, Ginamarie Foglia, Guy De Bruyn, Sanjay Gurunathan
  • Publication number: 20180110849
    Abstract: The disclosure relates to generally to the field of therapeutic and/or protective vaccination against Clostridium dificile (C. difficile). More specifically, it relates to methods for immunizing a host against C. difficile strains expressing C. difficile binary toxin (CDT) and strains not expressing CDT. These methods involve the administration to a host of an immunogenic composition comprising inactivated purified C. difficile Toxin A and purified Toxin B. The purified C. difficile toxins may be derived from a C. difficile strain that does not express CDT.
    Type: Application
    Filed: May 14, 2016
    Publication date: April 26, 2018
    Applicant: Sanofi Pasteur, Inc.
    Inventors: Laurence Quemeneur, Patricia Pietrobon, Patricia Ladono-Hayes, Steven HAUSER
  • Publication number: 20170304423
    Abstract: This disclosure relates to methods for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject. The subject may be at risk for a primary symptomatic C. difficile infection. In some embodiments, a method is for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject at risk for a primary symptomatic C. difficile infection, and comprises administering to the subject a composition comprising C. difficile toxoid A and toxoid B at least three times, each administration being about seven days apart.
    Type: Application
    Filed: July 10, 2017
    Publication date: October 26, 2017
    Applicant: Sanofi Pasteur, Inc.
    Inventors: Patricia Pietrobon, Ginamarie Foglia, Guy De Bruyn, Sanjay Gurunathan
  • Patent number: 9730994
    Abstract: This disclosure relates to methods for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject. The subject may be at risk for a primary symptomatic C. difficile infection. In some embodiments, a method is for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject at risk for a primary symptomatic C. difficile infection, and comprises administering to the subject a composition comprising C. difficile toxoid A and toxoid B at least three times, each administration being about seven days apart.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: August 15, 2017
    Assignee: SANOFI PASTEUR, INC.
    Inventors: Patricia Pietrobon, Ginamarie Foglia, Guy De Bruyn, Sanjay Gurunathan
  • Publication number: 20160120968
    Abstract: This disclosure relates to methods for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject. The subject may be at risk for a primary symptomatic C. difficile infection. In some embodiments, a method is for eliciting an immune response against C. difficile toxin A and toxin B in an adult human subject at risk for a primary symptomatic C. difficile infection, and comprises administering to the subject a composition comprising C. difficile toxoid A and toxoid B at least three times, each administration being about seven days apart.
    Type: Application
    Filed: June 13, 2014
    Publication date: May 5, 2016
    Applicant: Sanofi Pasteur, Inc.
    Inventors: Patricia Pietrobon, Ginamarie Foglia, Guy De Bruyn, Sanjay Gurunathan